AnaptysBio

Golfer devastated after just barely missing a putt
Biotech

AnaptysBio abandons rosnilimab for UC after phase 2 fail

AnaptysBio has abandoned plans to develop rosnilimab for ulcerative colitis after the PD-1 agonist flunked a phase 2 study.
James Waldron Nov 10, 2025 10:05am
direction arrow

Anaptys plans to split into 2 businesses

Sep 30, 2025 9:35am
blocks stack target climb build arrow meet

AnaptysBio's PD-1 drug reduces rheumatoid arthritis in phase 2

Feb 12, 2025 9:57am
Person throwing piece of paper into full waste bin

Anaptys scraps atopic dermatitis asset after ph. 2 fail

Dec 11, 2024 11:02am
MA

Anaptys picks up rival to Biogen autoimmune asset from Centessa

Nov 28, 2023 6:30am
Graphic of a number of arrows missing the bullseye on a target except for one arrow

Chasing Boehringer, Anaptys hits goal in skin disease phase 3

Oct 9, 2023 9:20am